Francisella tularensis T-Cell antigen identification using humanized HLA-DR4 transgenic mice

Clinical and Vaccine Immunology

Volumn 17, Issue 2, 2010, Pages 215-222

  Yu, Jieh Juen ^a   Goluguri, Tatareddy ^a   Guentzel, M Neal ^a   Chambers, James P ^a   Murthy, Ashlesh K ^a   Klose, Karl E ^a   Forsthuber, Thomas G ^a   Arulanandam, Bernard P ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; GAMMA INTERFERON; HLA DR4 ANTIGEN; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN B; T LYMPHOCYTE ANTIGEN; TRITON X 114; UNCLASSIFIED DRUG;

ALGORITHM; ALLELE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRANCISELLA TULARENSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; SCREENING; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

EID: 75749154457     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00361-09     Document Type: Article

References (60)

1. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
2. Anthony, L. S., and P. A. Kongshavn. 1987. Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb. Pathog. 2:3-14.
3. Baron, S. D., R. Singh, and D. W. Metzger. 2007. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect. Immun. 75:2152-2162.
4. Bhasin, M., A. Garg, and G. P. Raghava. 2005. PSLpred: prediction of subcellular localization of bacterial proteins. Bioinformatics 21:2522-2524.
5. Bhasin, M., and G. P. Raghava. 2004. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence. Bioinformatics 20:421-423.
6. Bordier, C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 256:1604-1607.
7. Breton, C., and A. Imberty. 1999. Structure/function studies of glycosyltransferases. Curr. Opin Struct. Biol. 9:563-571.
8. Brotcke, A., D. S. Weiss, C. C. Kim, P. Chain, S. Malfatti, E. Garcia, and D. M. Monack. 2006. Identification of MglA-regulated genes reveals novel virulence factors in Francisella tularensis. Infect. Immun. 74:6642-6655.
9. Clemens, D. L., B. Y. Lee, and M. A. Horwitz. 2004. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72:3204-3217.
10. Collins, J. T., and W. A. Dunnick. 1993. Germline transcripts of the murine immunoglobulin gamma-2A gene-structure and induction by IFN-gamma. Int. Immunol. 5:885-891.
11. Cong, Y., M. Jupelli, M. N. Guentzel, G. Zhong, A. K. Murthy, and B. P. Arulanandam. 2007. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine 25:3773-3780.
12. Cong, Y., J. J. Yu, M. N. Guentzel, M. T. Berton, J. Seshu, K. E. Klose, and B. P. Arulanandam. 2009. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (ΔiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine 27:5554-5561.
13. Cummings, E. D., J. M. Brown, S. T. Sarva, R. H. Waldo, and G. M. Hilliard. 2007. High-throughput proteomics processing of proteins in polyacrylamide in a multiwell format. J. Proteome Res. 6:1603-1608.
14. de Bruin, O. M., J. S. Ludu, and F. E. Nano. 2007. The Francisella pathogenicity island protein IglA localizes to the bacterial cytoplasm and is needed for intracellular growth. BMC Microbiol. 7:1.
15. Deng, K., R. J. Blick, W. Liu, and E. J. Hansen. 2006. Identification of Francisella tularensis genes affected by iron limitation. Infect. Immun. 74: 4224-4236.
16. Dumetz, F., E. Duchaud, S. E. LaPatra, C. Le Marrec, S. Claverol, M. C. Urdaci, and M. Le Henaff. 2006. A protective immune response is generated in rainbow trout by an OmpH-like surface antigen (P18) of Flavobacterium psychrophilum. Appl. Environ. Microbiol. 72:4845-4852.
17. Eigelsbach, H. T., J. J. Tulis, E. L. Overholt, and W. R. Griffith. 1961. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc. Soc. Exp. Biol. Med. 108:732-734.
18. Elkins, K. L., A. Cooper, S. M. Colombini, S. C. Cowley, and T. L. Kieffer. 2002. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect. Immun. 70:1936-1948.
19. Elkins, K. L., S. C. Cowley, and C. M. Bosio. 2007. Innate and adaptive immunity to Francisella. Ann. N. Y. Acad. Sci. 1105:284-324.
20. Finco, O., A. Bonci, M. Agnusdei, M. Scarselli, R. Petracca, N. Norais, G. Ferrari, I. Garaguso, M. Donati, V. Sambri, R. Cevenini, G. Ratti, and G. Grandi. 2005. Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine 23:1178-1188.
21. Forsthuber, T. G., C. L. Shive, W. Wienhold, K. de Graaf, E. G. Spack, R. Sublett, A. Melms, J. Kort, M. K. Racke, and R. Weissert. 2001. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLADR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells. J. Immunol. 167:7119-7125.
22. Frank, D. W., and T. C. Zahrt. 2007. Genetics and genetic manipulation in Francisella tularensis. Ann. N. Y. Acad. Sci. 1105:67-97.
23. Garg, R., J. K. Srivastava, A. Pal, S. Naik, and A. Dube. 2005. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine 23:1189-1196.
24. Gross, D. M., T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z. A. Nagy, J. A. Field, A. C. Steere, and B. T. Huber. 1998. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281: 703-706.
25. Hager, A. J., D. L. Bolton, M. R. Pelletier, M. J. Brittnacher, L. A. Gallagher, R. Kaul, S. J. Skerrett, S. I. Miller, and T. Guina. 2006. Type IV pilimediated secretion modulates Francisella virulence. Mol. Microbiol. 62:227-237.
26. Hendrix, L. R., L. P. Mallavia, and J. E. Samuel. 1993. Cloning and sequencing of Coxiella burnetii outer membrane protein gene com1. Infect. Immun. 61:470-477.
27. Hornick, R. B., and H. T. Eigelsbach. 1966. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30:532-538.
28. Hung, C. Y., N. M. Ampel, L. Christian, K. R. Seshan, and G. T. Cole. 2000. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. Infect. Immun. 68:584-593.
29. Ito, K., H. J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D. R. Bolin, R. Arceo, R. Campbell, F. Falcioni, D. Vidovic, J. Hammer, and Z. A. Nagy. 1996. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183:2635-2644.
30. Kanehisa, M., and S. Goto. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27-30.
31. Kohn, D. F., S. K. Wixson, W. J. White, and G. J. Benson. 1997. Anesthesia and analgesia in laboratory animals. Academic Press, New York, NY.
32. Lauriano, C. M., J. R. Barker, F. E. Nano, B. P. Arulanandam, and K. E. Klose. 2003. Allelic exchange in Francisella tularensis using PCR products. FEMS Microbiol. Lett. 229:195-202.
33. Lauriano, C. M., J. R. Barker, S. S. Yoon, F. E. Nano, B. P. Arulanandam, D. J. Hassett, and K. E. Klose. 2004. MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc. Natl. Acad. Sci. U. S. A. 101:4246-4249.
34. + T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J. Immunol. 180:3375-3382.
35. Marchler-Bauer, A., J. B. Anderson, F. Chitsaz, M. K. Derbyshire, C. De-Weese-Scott, J. H. Fong, L. Y. Geer, R. C. Geer, N. R. Gonzales, M. Gwadz, S. He, D. I. Hurwitz, J. D. Jackson, Z. Ke, C. J. Lanczycki, C. A. Liebert, C. Liu, F. Lu, S. Lu, G. H. Marchler, M. Mullokandov, J. S. Song, A. Tasneem, N. Thanki, R. A. Yamashita, D. Zhang, N. Zhang, and S. H. Bryant. 2009. CDD: specific functional annotation with the Conserved Domain Database. Nucleic Acids Res. 37:D205-D210.
36. Meens, J., M. Selke, and G. F. Gerlach. 2006. Identification and immunological characterization of conserved Mycoplasma hyopneumoniae lipoproteins Mhp378 and Mhp651. Vet. Microbiol. 116:85-95.
37. Mohapatra, N. P., A. Balagopal, S. Soni, L. S. Schlesinger, and J. S. Gunn. 2007. AcpA is a Francisella acid phosphatase that affects intramacrophage survival and virulence. Infect. Immun. 75:390-396.
38. Mori, M., P. G. Beatty, M. Graves, K. M. Boucher, and E. L. Milford. 1997. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64:1017-1027.
39. Murthy, A. K., Y. Cong, C. Murphey, M. N. Guentzel, T. G. Forsthuber, G. Zhong, and B. P. Arulanandam. 2006. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect. Immun. 74:6722-6729.
40. Pammit, M. A., V. N. Budhavarapu, E. K. Raulie, K. E. Klose, J. M. Teale, and B. P. Arulanandam. 2004. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob. Agents Chemother. 48:4513-4519.
41. Pammit, M. A., E. K. Raulie, C. M. Lauriano, K. E. Klose, and B. P. Arulanandam. 2006. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect. Immun. 74:2063-2071.
42. Parkinson, G. N., J. V. Skelly, and S. Neidle. 2000. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med. Chem. 43:3624-3631.
43. + T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol. Cell Biol. 86:515-522.
44. + T cells and antibodies, including immunoglobulin A. Clin. Vaccine Immunol. 16:444-452.
45. Rohmer, L., C. Fong, S. Abmayr, M. Wasnick, T. J. L. Freeman, M. Radey, T. Guina, K. Svensson, H. S. Hayden, M. Jacobs, L. A. Gallagher, C. Manoil, R. K. Ernst, B. Drees, D. Buckley, E. Haugen, D. Bovee, Y. Zhou, J. Chang, R. Levy, R. Lim, W. Gillett, D. Guenthener, A. Kang, S. A. Shaffer, G. Taylor, J. Z. Chen, B. Gallis, D. A. D'Argenio, M. Forsman, M. V. Olson, D. R. Goodlett, R. Kaul, S. I. Miller, and M. J. Brittnacher. 2007. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome Biol. 8:R102.
46. Sanchez-Ferrer, A., R. Bru, and F. Garcia-Carmona. 1994. Phase separation of biomolecules in polyoxyethylene glycol nonionic detergents. Crit. Rev. Biochem. Mol. Biol. 29:275-313.
47. Santic, M., M. Molmeret, and K. Y. Abu. 2005. Modulation of biogenesis of the Francisella tularensis subsp. novicida-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN-gamma. Cell. Microbiol. 7:957-967.
48. Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 134-146.
49. Sebastian, S., J. T. Pinkham, J. G. Lynch, R. A. Ross, B. Reinap, L. T. Blalock, J. W. Conlan, and D. L. Kasper. 2009. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27:597-605.
50. Sinha, S., K. Kosalai, S. Arora, A. Namane, P. Sharma, A. N. Gaikwad, P. Brodin, and S. T. Cole. 2005. Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology 151: 2411-2419.
51. Sjostedt, A. 2005. Francisella, p. 200-210. In D. J. Brenner, J. T. Staley, and G. M. Garrity (ed.), Bergey's manual of systematic bacteriology. The proteobacteria, part B, vol. 2, 2nd ed. Springer, New York, NY.
52. Sjostedt, A. 2007. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N. Y. Acad. Sci. 1105:1-29.
53. Stuart, B. M., and R. L. Pullen. 1945. Tularemic pneumonia: review of American literature and report of 15 additional cases. Am. J. Med. Sci. 210:223-236.
54. Surcel, H. M. 1990. Diversity of Francisella tularensis antigens recognized by human T lymphocytes. Infect. Immun. 58:2664-2668.
55. Surcel, H. M., J. Ilonen, K. Poikonen, and E. Herva. 1989. Francisella tularensis-specific T-cell clones are human leukocyte antigen class II restricted, secrete interleukin-2 and gamma interferon, and induce immunoglobulin production. Infect. Immun. 57:2906-2908.
56. Tarnvik, A., M. L. Lofgren, S. Lofgren, G. Sandstrom, and H. Wolf-Watz. 1985. Long-lasting cell-mediated immunity induced by a live Francisella tularensis vaccine. J. Clin. Microbiol. 22:527-530.
57. Tatusov, R. L., E. V. Koonin, and D. J. Lipman. 1997. A genomic perspective on protein families. Science 278:631-637.
58. Wang, L., and R. L. Coppel. 2002. Triton X-114 phase partitioning for antigen characterization. Methods Mol. Med. 72:581-585.
59. Wu, T. H., J. A. Hutt, K. A. Garrison, L. S. Berliba, Y. Zhou, and C. R. Lyons. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect. Immun. 73: 2644-2654.
60. Yoshida, Y., Y. Nakano, Y. Yamashita, and T. Koga. 1998. Identification of a genetic locus essential for serotype b-specific antigen synthesis in Actinobacillus actinomycetemcomitans. Infect. Immun. 66:107-114.